|Bid||171.91 x 800|
|Ask||171.97 x 900|
|Day's Range||171.68 - 172.80|
|52 Week Range||85.00 - 174.63|
|Beta (3Y Monthly)||1.29|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
- Gilead to Make $3.95 Billion Upfront Payment and $1.1 Billion Equity Investment - - Gilead Gains Access to Galapagos' Differentiated Drug Discovery Platform and Current.
As a result of this discussion, a path forward has been established to submit the NDA for filgotinib as a treatment for rheumatoid arthritis in 2019. Filgotinib is an investigational agent and not approved anywhere globally. Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases.
Mechelen, Belgium; 20 June 2019, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises..
Mechelen, Belgium; 17 June 2019; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from The Capital Group.
ROCCELLA is a multi-regional, randomized, double-blind, placebo-controlled, dose ranging trial evaluating the efficacy and safety of three different once-daily oral doses of GLPG1972/S201086 in patients with knee osteoarthritis (OA). ROCCELLA includes more than 850 patients in 12 countries in Europe, Asia, North and South America. Galapagos is responsible for ROCCELLA in the United States, where more than 300 patients were recruited. Servier is responsible for this trial in all other countries, where the rest of the patients were recruited.
-- Phase 3 FINCH 1 and FINCH 3 Data of Filgotinib in Rheumatoid Arthritis to Be Featured in Opening Plenary and Late Breaker Sessions -- Foster City, Calif. and Mechelen,.
Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that data on filgotinib, an investigational, oral, selective JAK1 inhibitor, will be presented at the Annual European Congress of Rheumatology (EULAR 2019) in Madrid, Spain, on June 12-15, 2019. Among the abstracts to be presented are 24 week interim results from the ongoing FINCH 1 and FINCH 3 Phase 3 studies evaluating filgotinib in adults with rheumatoid arthritis.
Key Q1 2019 results: Group revenues of €40.9 million Operating loss €53.2 million Net loss of €48.7 million End of first quarter cash and cash equivalents €1.2 billion.
Mechelen, Belgium and Planegg/Munich, Germany; 23 April 2019; 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX;.
On 10 April 2019, the board of directors of Galapagos approved "Warrant Plan 2019 RMV," intended for the employees of its French subsidiary, Galapagos SASU, and "Warrant Plan 2019", intended mainly for the employees of the company and its subsidiaries, and for directors and an independent consultant of the company, within the framework of the authorized capital. Under these warrant plans, 2,070,000 warrants were created, subject to acceptances, and offered to the beneficiaries of the plans.
Nomination of Mr. Peter Guenter for Galapagos' board of directors Mechelen, Belgium; 29 March 2019, 22.15 CET; regulated information - Galapagos NV (Euronext & NASDAQ:.
-- Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety Profile -- Foster City,.
-- Filgotinib 100 mg and 200 mg Plus Methotrexate Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone --
-- Filgotinib 100 mg and 200 mg Doses Demonstrated Significantly Higher ACR20/50/70 Responses than Placebo in Patients with Prior Inadequate Methotrexate Response --
-- Filgotinib 100 mg and 200 mg Plus Methotrexate (MTX) Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone -- -- Filgotinib Safety Profile.
-- Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety Profile --
-- Filgotinib 100 mg and 200 mg Doses Demonstrated Significantly Higher ACR20/50/70 Responses than Placebo in Patients with Prior.
NEW YORK, March 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Revenues doubled in 2018 Key 2018 clinical results: FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with.
7 February 2019, 7.30 CET - Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809), and Galapagos NV (Euronext & NASDAQ: GLPG) today announced a global collaboration focused on a novel target for fibrosis and other indications. The collaboration concerns a small-molecule program, currently in pre-clinical drug development for the treatment of fibrotic diseases of the liver and other organs. The target has been identified and validated using Evotec's proprietary platforms for fibrotic diseases and NASH.
Mechelen, Belgium; 8 January 2019; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Sands Capital.
7 January 2019, 7.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) initiated a Phase 1 trial with GLPG3312, a first generation compound against a novel and undisclosed inflammation target class discovered by Galapagos. "We are excited by the rapid progression of our Toledo program into the clinic," said Dr. Piet Wigerinck, Chief Scientific Officer at Galapagos.
6 January 2019, 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) expands its clinical study program with GLPG1690 in systemic sclerosis, following the recent start of the ISABELA Phase 3 program with '1690 in IPF. NOVESA is a double-blind, placebo-controlled Phase 2a trial evaluating the efficacy, safety and PK/PD of '1690 in patients with systemic sclerosis (SSc, or scleroderma). NOVESA is planned to recruit 30 patients with diffuse cutaneous SSc, an autoimmune disease involving multiorgan fibrosis, which has one of the highest mortality rates among rheumatic diseases.
4 January 2019, 22.01 CET - Fibrocor Therapeutics L.P. (Fibrocor), a privately held Canadian company, and Galapagos NV (Euronext & NASDAQ: GLPG) announced a global partnership focused on a novel target for idiopathic pulmonary fibrosis (IPF) and other indications. In exchange for global commercialization rights to Galapagos, Fibrocor will receive an upfront payment, and potentially is eligible for further milestone and royalty payments. Galapagos will be responsible for all further development of the program.